Sign up to save your podcasts
Or
Share MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the tools used to predict response to immunotherapy, and they review emerging biomarkers.
The multidisciplinary team:
- Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/
View all episodes
By touchpodcasttouchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the tools used to predict response to immunotherapy, and they review emerging biomarkers.
The multidisciplinary team:
- Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/